ActaStim-S
Theragen, Inc. · Decision date May 13, 2026
What did the FDA approve?
FDA records P190030/S004 as a supplement to PMA P190030, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated May 13, 2026.
FDA approval order statement
Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Orthopedic
- Decision date
- May 13, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P190030/S004
- Regulatory pathway
- PMA supplement
- Applicant
- Theragen, Inc.
- Product code
- LOF
- Decision code
- APPR
- Decision date
- May 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, bone growth, non-invasive.
- Applicant
- Theragen, Inc.
- Product code
- LOF
- FDA device class
- 2
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P190030/S004 received
Application receipt date recorded by FDA.
P190030/S004 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P190030. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Djo, LLC | 510(k) clearance | Sep 29, 2026 | FDA | |
| Bioventus, LLC | PMA supplement | Mar 6, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Theragen, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 11220 Assett Loop, Suite 101, Manassas, VA, 20109
Sources and methodology
- Original FDA record: P190030/S004
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
